Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (TSE:ONC)
TSX:ONC
RESEARCH TOOLSreports
Oncolytics Biotech (ONC) Stock Price & Analysis
155 Followers
ONC Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$1.20 - C$4.49
Previous CloseC$1.43
Volume23.15K
Average Volume (3M)83.69K
Market Cap
C$107.85M
Enterprise ValueC$73.36M
Total Cash (Recent Filing)C$34.91M
Total Debt (Recent Filing)C$423.00K
Price to Earnings (P/E)-3.5
Beta0.84
Next Earnings
May 03, 2024EPS Estimate
-C$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding73,368,847
10 Day Avg. Volume122,555
30 Day Avg. Volume83,685
Standard Deviation0.49
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)3.91
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.35Price Target Upside343.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Oncolytics Biotech News
PremiumCompany Announcements
Oncolytics Biotech Sets Virtual Annual MeetingPremiumCompany Announcements
Oncolytics Biotech Eyes Milestone in Breast Cancer Trial
PremiumCompany Announcements
Oncolytics Biotech Targets FDA Approval for Cancer Drug
PremiumCompany Announcements
Oncolytics Biotech Showcases at Oncology Event
PremiumCompany Announcements
Oncolytics Biotech Showcases at Oncology Conference
PremiumCompany Announcements
Oncolytics Biotech Shows Promising Cancer Drug ProgressBulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe P3 registrational trial in 1L pancreatic cancer is on track to start later in the year, showcasing the company's commitment to addressing this challenging disease with potential new therapies.
Strategic CollaborationsThe management's optimism about a potential clinical path that includes a collaboration with a major biopharmaceutical company could lead to enhanced credibility and financial backing for the company's pipeline.
Upcoming Data ReleasesAnticipation is building for the release of overall survival data from the P2 BRACELET-1 trial in metastatic breast cancer, which could significantly impact the stock if results are positive.
Bears Say
Capital RiskModel gross equity raises could significantly dilute existing shareholders' value.
Clinical DevelopmentPelareorep's exclusion from Precision Promise may negatively impact Oncolytics' clinical progress and investor confidence.
EarningsOncolytics reported a net loss, indicating potential financial challenges ahead.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.61%
Insiders
0.06% Mutual Funds
0.39% Other Institutional Investors
96.94% Public Companies and
Individual Investors
ONC FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was C$1.20 and its highest was C$4.49 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Currently, no data Available
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is May 03, 2024 which is in 9 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Mar 07, 2024. The company reported -C$0.05 earnings per share for the quarter, beating the consensus estimate of -C$0.148 by C$0.098.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -C$0.11.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 75,419,770 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -C$0.05 in its last earnings report, beating expectations of -C$0.148. Following the earnings report the stock price went up 0.709%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in TSE:ONC
---
Oncolytics Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$6.35 (343.81% Upside)
C$6.35 (343.81% Upside)
Blogger Sentiment
Bullish
TSE:ONC Sentiment 66%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.14%
12-Months-Change
Fundamentals
Return on Equity
-101.82%
Trailing 12-Months
Asset Growth
6.85%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
---
ONC Earnings Call
Q4 2024
0:00 / 0:00
---
ONC Stock 12 Months Forecast
Average Price Target
C$6.35
▲(343.81% Upside)
Technical Analysis
Best Analysts Covering ONC
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+13.14%
reiterated a buy rating 11 months ago
Copying Douglas Loe's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +13.14% per trade.
---